Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.55 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95889 | 0.98 | PTPN1 (0.74) | PTPN1HPGDRAB9ANAMPTLMNA | |
| SCHEMBL28656982 | 0.88 | PTPN1 (0.89) | PTPN1HPGDRAB9ANAMPTLMNA | |
| SCHEMBL125695 | 0.88 | PTPN1 (0.89) | PTPN1HPGDRAB9ANAMPTLMNA | |
| SCHEMBL22919689 | 0.82 | PTPN1 (0.72) | PTPN1HPGDRAB9ANAMPTLMNA | |
| SCHEMBL62827 | 0.81 | PTPN1 (0.71) | PTPN1HPGDRAB9ANAMPTLMNA | |
| SCHEMBL9198985 | 0.81 | PTPN1 (0.71) | PTPN1HPGDRAB9ANAMPTLMNA | |
| SCHEMBL1339196 | 0.81 | PTPN1 (0.71) | PTPN1HPGDRAB9ANAMPTLMNA | |
| SCHEMBL4448787 | 0.81 | PTPN1 (0.71) | PTPN1HPGDRAB9ANAMPTLMNA | |
| SCHEMBL29057710 | 0.81 | PTPN1 (0.77) | PTPN1HPGDRAB9ANAMPTLMNA | |
| SCHEMBL9851155 | 0.81 | PTPN1 (0.77) | PTPN1HPGDRAB9ANAMPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4361148-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | Albius Sciences Alpha Private Limited (SG) | 2024-05-01 | — | — | EP | disclosed |
| CN-117730079-A | Heterocyclyl-substituted polyheterazoles derivatives as medicaments for the treatment and/or prophylaxis of RSV infections | 亚博思生物科技(第一)有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-3838901-B1 | COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES | IRIMAJIRI THERAPEUTICS INC (JP) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022270628-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | 国立大学法人 大分大学 | 2022-12-29 | — | — | WO | disclosed |
| CN-115260193-A | Compounds and methods for treating rabies | 株式会社大分大学先端医学研究所 | 2022-11-01 | — | — | CN | disclosed |
| CN-112839944-B | Compounds and methods for treating rabies | 株式会社大分大学先端医学研究所 | 2022-08-05 | — | — | CN | disclosed |
| EP-3838901-A1 | COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES | Oita University Institute of Advanced Medicine, Inc. (JP) | 2021-06-23 | — | — | EP | disclosed |
| CN-112839944-A | Compounds and methods for treating rabies | 株式会社大分大学先端医学研究所 | 2021-05-25 | — | — | CN | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | PTPN1 1236/4885HPGD 2146/4885RAB9A 3886/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | PTPN1 1691/4885HPGD 2322/4885RAB9A 2273/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | PTPN1 1691/4885HPGD 2322/4885RAB9A 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.